Thiabendazole Tablets Suppliers & Bulk Manufacturers
Available Forms: Tablets
Available Strengths: 500 mg
Reference Brands: Mintezol(US), Tebanic(EU)
Category:
Anthelmintic
Thiabendazole inhibits microtubule formation in parasites, disrupting nutrient absorption and leading to their death. It effectively treats intestinal worms like roundworms and hookworms, as well as skin infestations. Benefits include rapid symptom relief, parasite eradication, reduced transmission, and supporting gastrointestinal and dermatological health worldwide.
Thiabendazole tablets is available in Tablets
and strengths such as 500 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Thiabendazole tablets is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Thiabendazole tablets can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Thiabendazole tablets, marketed as Mintezol and Tebanic, are approved in the US by the FDA and in the EU via EMA for treating parasitic infections. Regulatory approval requires detailed dossiers including clinical efficacy, safety data, manufacturing standards, and pharmacovigilance plans. The FDA reviews clinical trial and quality data, while the EMA ensures compliance with regional safety and manufacturing regulations. For guidance on dossier preparation, regulatory pathways, and market access, visit PharmaTradz. Proper compliance supports timely approval, safe use, and global availability, effectively managing intestinal and skin parasitic infections worldwide, supporting health efforts against parasitic diseases.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing